Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 trial of MK-1568 in prostate cancer
NL-OMON61808Phase 1Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2026
- Countries
- 1
01
Overview
Phase 1 trial of MK-1568 in prostate cancer (PCa), sponsored by Merck & Co. Primary endpoint: Primary endpoint(s). Planned start Dec 2026; status: not yet recruiting.
02
Drugs
MK-1568
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON61808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61808.